J. Moolman

发表

Ischemic preconditioning: Infarct size is a more reliable endpoint than functional recovery

A. Lochner, S. Genade, J. Moolman, 2003, Basic Research in Cardiology.

Nitric oxide: a trigger for classic preconditioning?

A. Lochner, S. Genade, E. Marais, 2000, American journal of physiology. Heart and circulatory physiology.

p38 MAPK activation triggers pharmacologically-induced beta-adrenergic preconditioning, but not ischaemic preconditioning.

A. Lochner, S. Genade, H. Strijdom, 2001, Journal of molecular and cellular cardiology.

The effect of integrated reporting on integrated thinking between risk, opportunity and strategy and the disclosure of risks and opportunities

M. Oberholzer, M. Steyn, J. Moolman, 2019, Southern African Business Review.

Melatonin protects against ischaemic-reperfusion myocardial damage.

A. Lochner, R. Salie, I. Harper, 2001, Journal of molecular and cellular cardiology.

Ischemic preconditioning and the beta-adrenergic signal transduction pathway.

A. Lochner, S. Genade, T. Podzuweit, 1999, Circulation.

Proposing a network of advisors that could guide a professional athlete’s financial decisions in pursuit of sustainable financial well-being

J. Moolman, 2020, Managing Sport and Leisure.

A newly created splice donor site in exon 25 of the MyBP-C gene is responsible for inherited hypertrophic cardiomyopathy with incomplete disease penetrance.

M. Gautel, W. McKenna, H. Vosberg, 2000, Circulation.

The many faces of H89: a review.

A. Lochner, A Lochner, J A Moolman, 2006, Cardiovascular drug reviews.

Protection of the ischaemic heart: investigations into the phenomenon of ischaemic preconditioning

A. Lochner, S. Genade, E. Marais, 2009, Cardiovascular journal of Africa.